Abstract
The last decade brought many new treatment options that changed the treatment algorithms for metastatic castrate-resistant prostate cancer (mCRPC). One of the most challenging tasks today is the optimal sequencing of agents since timing and patient selection are crucial to maximizing the therapeutic benefit. Docetaxel plays an important role in prostate cancer management and is likely to remain the same given the dramatic survival advantage in patients with newly diagnosed metastatic disease. A few phase III studies are currently testing the role of cabazitaxel as a frontline chemotherapy. Cleary, more research is needed to refine our understanding of predictors of response that will hopefully answer the question of how to sequence available treatments in order to maximize survival advantage. Discovery of predictive biomarkers has become one of the top priorities in prostate cancer research.
